On this week’s episode of “The Readout Loud”: a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news.

The turmoil at the Food and Drug Administration continues: Richard Pazdur has announced his retirement from the agency, just a month after taking the job as top drug regulator. He’s being replaced by Covid contrarian Tracy Beth Høeg . We also discuss a U.K.-U.S pharma trade agreement , a very large financing round for an AI-tinged longevity startup , and a big Phase 3 study win for Capricor Therapeutics and its Duchenne muscular dystrophy cell therapy.

Our special guest this week is David Olson, director of the UC Davis Institute for Psy

See Full Page